Die Rolle der Knochenumbaumarker bei Knochenmetastasen

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Osteologie/Osteology

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1055/s-0037-1619879
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• a of Assessment of bone response to systemic therapy in an trial: preliminary with the use of cross-link

  2021cited by this paper
• A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma

  2009cited by this paper
• Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.

  2009cited by this paper
• Osteocalcin is not a marker of progress in multiple myeloma

  2009cited by this paper
• Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

  2008influential reference
• Negative Regulation of the Osteoblast Function in Multiple Myeloma through the Repressor Gene E4BP4 Activated by Malignant Plasma Cells

  2008cited by this paper
• Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity

  2008cited by this paper
• Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

  2008cited by this paper
• Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma.

  2008cited by this paper
• Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases

  2008influential reference
• Changes of Biochemical Markers of Bone Turnover and YKL-40 Following Hormonal Treatment for Metastatic Prostate Cancer Are Related to Survival

  2007cited by this paper
• Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.

  2007cited by this paper
• Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.

  2007cited by this paper
• Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer

  2007cited by this paper
• Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study.

  2006cited by this paper
• Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.

  2006cited by this paper
• Serum Amino-Terminal Propeptide of Type 1 Procollagen (P1NP) in Prostate Cancer: A Potential Predictor of Bone Metastases and Prognosticator for Disease Progression and Survival

  2006cited by this paper
• Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.

  2006cited by this paper
• Tartrate-Resistant Acid Phosphatase 5b Activity Is a Useful Bone Marker for Monitoring Bone Metastases in Breast Cancer Patients after Treatment

  2006cited by this paper
• The Relative Use of Eight Collagenous and Noncollagenous Markers for Diagnosis of Skeletal Metastases in Breast, Prostate, or Lung Cancer Patients

  2006cited by this paper
• Crosstalk between cancer cells and bone microenvironment in bone metastasis.

  2005cited by this paper
• Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

  2005cited by this paper
• Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.

  2005cited by this paper
• [Biochemical markers of bone remodeling].

  2005cited by this paper
• Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

  2005cited by this paper
• Thousands of families to sue over retained organs

  2004influential reference
• Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis.

  2004cited by this paper
• An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone.

  2004influential reference
• Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.

  2004cited by this paper
• Tartrate-Resistant Acid Phosphatase 5b as a Serum Marker of Bone Metastasis in Breast Cancer Patients

  2004cited by this paper
• Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.

  2004cited by this paper
• Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.

  2004cited by this paper
• Pyridinoline cross‐links as markers for primary and secondary bone tumors

  2003cited by this paper
• Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer.

  2003cited by this paper
• Bone resorption predicts for skeletal complications in metastatic bone disease

  2003cited by this paper
• Diagnostic value of bone and tumour markers in patients with malignant diseases.

  2003influential reference
• Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer.

  2003cited by this paper
• Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer.

  2003cited by this paper
• Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.

  2003cited by this paper
• The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

  2003cited by this paper
• Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism.

  2003cited by this paper
• Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples

  2003cited by this paper
• Bone remodeling markers in the detection of bone metastases in prostate cancer.

  2003cited by this paper
• Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients.

  2002cited by this paper
• Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.

  2002cited by this paper
• Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases

  2002cited by this paper
• Cross-linked collagen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer.

  2002influential reference
• Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate.

  2002cited by this paper
• Markers of bone turnover do not predict bone metastases in breast cancer.

  2002cited by this paper
• Usefulness of bone markers for detection of bone metastases in lung cancer patients.

  2002cited by this paper
• Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases.

  2002influential reference
• Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.

  2002cited by this paper
• The serum level of the amino‐terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone

  2001cited by this paper
• A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.

  2001cited by this paper
• Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma

  2001cited by this paper
• Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer

  2001cited by this paper
• Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases.

  2001cited by this paper
• Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.

  2001cited by this paper
• Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer.

  2001cited by this paper
• Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.

  2001cited by this paper
• Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis

  2001cited by this paper
• Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.

  2001cited by this paper
• Interlaboratory variation of biochemical markers of bone turnover.

  2001cited by this paper
• Evaluation of bone metabolic markers in breast cancer with bone metastasis

  2001cited by this paper
• Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients

  2000cited by this paper
• Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases

  2000cited by this paper
• Tumor bone diseases and osteoporosis in cancer patients : pathophysiology, diagnosis, and therapy

  2000cited by this paper
• Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma

  2000cited by this paper
• Relationship of plasma bone cytokines with hypercalcemia in cancer patients.

  2000cited by this paper
• Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.

  2000cited by this paper
• Effects of Tamoxifen and Toremifene on Urinary Excretion of Pyridinoline and Deoxypyridinoline and Bone Density in Postmenopausal Patients with Breast Cancer

  1999cited by this paper
• Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.

  1999cited by this paper
• Novel Serum Markers of Bone Resorption: Clinical Assessment and Comparison with Established Urinary Indices

  1999influential reference
• Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.

  1999cited by this paper
• Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients

  1999cited by this paper
• Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

  1999cited by this paper
• Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios

  1999cited by this paper
• Long‐term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma

  1998cited by this paper
• Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain.

  1998cited by this paper
• Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen.

  1997cited by this paper
• Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease.

  1997cited by this paper
• Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.

  1997cited by this paper
• Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity

  1997cited by this paper
• Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP.

  1997cited by this paper
• Comparison of Assay of Total and Bone-Specific Alkaline Phosphatase in the Assessment of Osteoblast Activity in Patients with Metastatic Bone Disease

  1997cited by this paper
• Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease.

  1996cited by this paper
• Expression of bone sialoprotein in primary human breast cancer is associated with poor survival

  1996cited by this paper
• The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease.

  1995cited by this paper
• The short term effects of tamoxifen on bone turnover in older women.

  1995influential reference
• Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.

  1995influential reference
• Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast

  1993cited by this paper
• Changes of bone metabolic markers in patients with bone metastases: clinical significance in assessing bone response to chemotherapy.

  1993cited by this paper
• Serum osteocalcin concentrations in patients with multiple myeloma — correlation with disease stage and survival

  1992cited by this paper
• Pyridinium crosslinks as markers of bone resorption in patients with breast cancer.

  1991cited by this paper
• Abnormal serum bone gla protein levels in multiple myeloma: Crucial role of bone formation and prognostic implications

  1990influential reference
• The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism

  1987cited by this paper

• Das Mammakarzinom beim Mann

  2017cites this paper